Last update 26 Dec 2024
Levocetirizine dihydrochloride/Montelukast Sodium
Last update 26 Dec 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Levocetirizine/montelukast, Montelukast/levocetirizine, HCP 1102 + [2] |
Target |
Mechanism CysLT1 antagonists(Cysteinyl leukotriene receptor 1 antagonists), H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure
Molecular FormulaC21H27Cl3N2O3 |
InChIKeyPGLIUCLTXOYQMV-GHVWMZMZSA-N |
CAS Registry130018-87-0 |
View All Structures (2)
Related
5
Clinical Trials associated with Levocetirizine dihydrochloride/Montelukast SodiumEfficacy and Safety of HCP1102 in Patients With Perennial Allergic Rhinitis : A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial
A Randomized, Open Label, Single Dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of HCP1102 in Comparison to HGP0813 and HGP1408 Administered in Healthy Male Volunteers
Efficacy and Safety of HCP1102 Capsule : A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial
100 Clinical Results associated with Levocetirizine dihydrochloride/Montelukast Sodium
Login to view more data
100 Translational Medicine associated with Levocetirizine dihydrochloride/Montelukast Sodium
Login to view more data
100 Patents (Medical) associated with Levocetirizine dihydrochloride/Montelukast Sodium
Login to view more data
100 Deals associated with Levocetirizine dihydrochloride/Montelukast Sodium
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Rhinitis, Allergic, Perennial | Phase 3 | KR | 23 Oct 2018 | |
| allergic rhinitis with asthma | Phase 3 | KR | 01 Sep 2014 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT02552667 (Pubmed) Manual  | Phase 3 | 228 | ybdthskcdj(ylvnaflnyn) = lyhkfzapnl twlaebbzjm (kyaahuljrz, 0.06) | Superior | 01 Jul 2018 | ||
montelukast | ybdthskcdj(ylvnaflnyn) = qayhtmtyge twlaebbzjm (kyaahuljrz, 0.06) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free